Thor Medical Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
There is insufficient data on Thor Medical's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | n/a |
| Return on equity | -2.0% |
| Net Margin | n/a |
| Next Earnings Update | 26 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Thor Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -6 | 3 | 0 |
Quality Earnings: TRMEDO is currently unprofitable.
Growing Profit Margin: TRMEDO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if TRMEDO's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare TRMEDO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TRMEDO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.1%).
Return on Equity
High ROE: TRMEDO has a negative Return on Equity (-2.05%), as it is currently unprofitable.